Vignal-Clermont Catherine

Sergott Robert C, Carelli Valerio, Newman Nancy J, Biousse Valérie, Yu-Wai-Man Patrick, Vignal-Clermont Catherine et al.

This study found that better baseline vision and thicker retinal nerve fiber and ganglion cell layers predict improved visual outcomes 1.5 years after gene therapy for LHON.

Yu-Wai-Man Patrick, Newman Nancy J, Biousse Valérie, Carelli Valerio, Moster Mark L, Vignal-Clermont Catherine et al.

Gene therapy for LHON (MT-ND4 variant) showed sustained bilateral visual improvement and good safety up to five years, offering promising long-term benefit for patients.

Boussion François, Guindolet Damien, Deschamps Romain, Lamirel Cédric, Vignal-Clermont Catherine

This study found the pRNFL/BMO-MRW ratio effectively differentiates glaucoma from other optic neuropathies. This ratio, reflecting optic nerve head architecture, provides a valuable objective diagnostic tool for clinical practice.

Vignal-Clermont Catherine, Yu-Wai-Man Patrick, Newman Nancy J, Carelli Valerio, Moster Mark L, Biousse Valerie et al.

Lenadogene nolparvovec gene therapy for LHON showed good long-term safety. Most ocular side effects were mild, manageable inflammation/IOP, resolving with topical steroids. Systemic tolerability was excellent.

Newman Nancy J, Yu-Wai-Man Patrick, Carelli Valerio, Moster Mark L, Biousse Valerie, Vignal-Clermont Catherine et al.

This gene therapy study for early LHON found no significant visual acuity difference between treated and sham eyes, suggesting limited direct benefit from the injection itself.